Forkhead box protein A2 mRNA (FOXA2)

Forkhead box protein A2 (FOXA2), also known as Hepatocyte Nuclear Factor 3-beta (HNF3B), is a pioneer transcription factor essential for the development of endoderm-derived organs such as the liver, pancreas, and lungs [1][2]. It functions by binding to condensed chromatin and facilitating the recruitment of other transcription factors, thereby regulating gene expression programs critical for organogenesis and adult homeostasis [3]. In the adult liver, FOXA2 regulates the expression of genes involved in glucose and lipid metabolism, particularly during fasting states [4]. In the respiratory system, it maintains the differentiation of airway epithelial cells and prevents mucus metaplasia; its loss is a hallmark of chronic inflammatory airway diseases like asthma and COPD [5]. Conversely, FOXA2 is often overexpressed in certain aggressive cancers, such as neuroendocrine prostate cancer and triple-negative breast cancer, where it promotes epithelial-mesenchymal transition (EMT) and metastasis [6]. Therapeutic targeting of FOXA2 mRNA using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) is being explored to modulate its levels in these disease contexts [7]. However, the broad physiological impact of FOXA2 necessitates precise, tissue-specific delivery to avoid systemic toxicity, such as metabolic disruption or impaired lung defense [7]. Currently, there are no FDA-approved drugs targeting FOXA2 mRNA, with most efforts remaining in the preclinical or discovery stages.

Other names

HNF3BHepatocyte nuclear factor 3-betaTranscription factor 3BTCF3B

Reduction of FOXA2 protein expression through targeted mRNA degradation via RNA interference or RNase H-mediated cleavage.